Ocular TraumaNCT07887425
Corneal Trauma Diagnostic Study
A study testing Tear fluid collection with mass spec analysis. in people with Ocular Trauma, run by InnSight Technology, Inc. at 1 site in United States.
Trial summary
Tear fluid will be collected from patients diagnosed with ocular trauma at the University of Pittsburgh Medical Center to evaluate biomarkers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Ocular Trauma
- What is being tested?
- Tear fluid collection with mass spec analysis.
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Nov 2026to Nov 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Minimum age of 18 years.
- Diagnosis of visually significant cataract and scheduled for routine cataract surgery at UPMC with a clear corneal incision or
- scheduled for clinical repair of a full-thickness corneal laceration.
Who cannot join
- Prior history of full-thickness corneal laceration from trauma or from a surgical procedure
- Current diagnosis of glaucoma or use of ocular hypotensive drops or oral aqueous suppressants.
- Actively being treated for the diagnosis of dry eyes with a topical drop other than artificial tears.
- Actively taking oral or topical supplementation of Vitamin C.
- Scheduled for additional eye surgeries, combined with the routine cataract surgery.
- Surgical plan that would include incisions in the clear for cataract extraction.
- Inability to provide informed consent due to suspected head trauma, altered mental status, or other factors impairing decision-making capacity.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
UPMC Vision Insititute - Mercy Pavilion
Pittsburgh, Pennsylvania, 15219
PI, 866-202-4296, info@innsightech.com
About this study
Official title: Tear Fluid Collection in Patients Before and After Corneal Incision or Trauma.
Tear fluid will be collected from patients diagnosed with ocular trauma at the University of Pittsburgh Medical Center to evaluate biomarkers.
Read the detailed description
Prospective, controlled, single-site, clinical trial evaluating tear fluid biomarkers in patients diagnosed with eye trauma at the University of Pittsburgh.
- Conditions
- Ocular Trauma
- Being tested
- Tear fluid collection with mass spec analysis.
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tear fluid collection with mass spec analysis.Diagnostic test
Tear fluid collection with mass spec analysis.
| Study group | Role | What they receive |
|---|---|---|
| Patients with ocular trauma | Experimental | Not described Receives: Diagnostic Test: Tear fluid collection with mass spec analysis. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Primary Outcome - Ascorbic Acid
Measurement of ascorbic acid using mass spec
Measured: One year.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Oct 2026
- Study startNov 2026 (estimated)
- Primary completionNov 2027 (estimated)
- Study completionNov 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ocular TraumaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- InnSight Technology, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07887425
- Sponsor's protocol ID
- STUDY25100166
- Other IDs
- HT942525CE044
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Tear Fluid Collection in Patients Before and After Corneal Incision or Trauma.
- ClinicalTrials.gov ID
- NCT07887425
- Acronym / sponsor ID
- STUDY25100166
- Conditions
- Ocular Trauma
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- InnSight Technology, Inc.Industry (pharma, biotech, devices)
- Study start
- Nov 2026 (estimated)
- Primary completion
- Nov 2027 (estimated)
- Study completion
- Nov 2027 (estimated)
- First posted
- 21 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Tear fluid will be collected from patients diagnosed with ocular trauma at the University of Pittsburgh Medical Center to evaluate biomarkers.
Detailed description
Prospective, controlled, single-site, clinical trial evaluating tear fluid biomarkers in patients diagnosed with eye trauma at the University of Pittsburgh.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with ocular trauma | Experimental | Diagnostic Test: Tear fluid collection with mass spec analysis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Minimum age of 18 years.
- Diagnosis of visually significant cataract and scheduled for routine cataract surgery at UPMC with a clear corneal incision or
- scheduled for clinical repair of a full-thickness corneal laceration.
Key exclusion criteria (7 listed)
- Prior history of full-thickness corneal laceration from trauma or from a surgical procedure
- Current diagnosis of glaucoma or use of ocular hypotensive drops or oral aqueous suppressants.
- Actively being treated for the diagnosis of dry eyes with a topical drop other than artificial tears.
- Actively taking oral or topical supplementation of Vitamin C.
- Scheduled for additional eye surgeries, combined with the routine cataract surgery.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tear fluid collection with mass spec analysis.Tear fluid collection with mass spec analysis. | Diagnostic test | Patients with ocular trauma |
Primary outcome
Primary Outcome - Ascorbic Acid
Time frame: One year.
Measurement of ascorbic acid using mass spec
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
Related trials for Ocular Trauma
Recruiting
The Effects of Vestibulo-Ocular Reflex Exercises Added to Postural Stabilization Training in Chronic Ankle Instability
Ankle Sprains, Ankle Sprain Strain
Recruiting
Inflammatory Mediators of Glaucoma After Corneal Transplantation (AH-Tears)
Glaucoma, Corneal Transplantation
RecruitingObservational study
The Correlation Between Red Cell Transfusion and Complications of Prematurity
Retinopathy of Prematurity (ROP), Bronchopulmonary Dysplasia (BPD)
RecruitingPhase 1
Safety of Cultured Allogeneic Adult Umbilical Cord or Placental Derived Mesenchymal Stem Cell Exosomes for NAION
Eye Diseases, Retinitis Pigmentosa
RecruitingPhase 1/2
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Tear fluid collection with mass spec analysis. in people with Ocular Trauma, run by InnSight Technology, Inc. at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact PI (866-202-4296, info@innsightech.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Primary Outcome - Ascorbic Acid (time frame: One year.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.